# Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease

> **NCT00918580** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 158 (actual)

## Conditions studied

- Pneumococcal Conjugate Vaccine

## Interventions

- **BIOLOGICAL:** 13-valent Pneumoccocal Conjugate Vaccine

## Key facts

- **NCT ID:** NCT00918580
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 158 (ACTUAL)
- **Last updated:** 2014-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00918580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00918580, "Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00918580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*